Broadcast Date: November 12, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
The integration of next-generation sequencing (NGS) into the diagnostic process for hematologic malignancies has greatly improved the accuracy and speed of confirming or refining the diagnosis and following minimal residual disease. Optimization of gene selection and assay development, together with skilled interpretation, are key factors in the execution of a clinically relevant NGS test for hematologic malignancies.
In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation. LeukoVantage covers the most important genes for myeloid diagnostics, with focused panels that allow rapid turnaround. N-of-One’s team of experienced PhDs provides expert, evidence-based annotation incorporating WHO, NCCN, and ELN guidelines, with clinically relevant information vetted by oncologists. N-of-One reports include diagnostic and prognostic information, therapeutic options, and clinical trials based on the unique combination of genomic alterations detected in each case. These reports are then reviewed, modified, and signed out by Quest pathologists.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Sheryl Krevsky Elkin, PhD
Chief Scientific Officer
N-of-One, a QIAGEN company
Frederick K. Racke, MD, PhD
Hematology/Oncology and Coagulation
Nichols Institute, San Juan Capistrano, CA